| Literature DB >> 31284349 |
Hyo-Ju Son1, Min Jae Kim1, Kyung Hwa Jung1, Sungim Choi1, Jiwon Jung1, Yong Pil Chong1, Sung-Han Kim1, Sang-Oh Lee1, Sang-Ho Choi1, Yang Soo Kim1, Jun Hee Woo1, Bong-Kwang Jung2, Hyemi Song2, Jong-Yil Chai2.
Abstract
The prevalence of human taeniasis has decreased in Korea. The stool egg positive proportion decreased from 1.9% in 1971 to 0% in 2004 in nationwide surveys. The neurocysticercosis (NCC) is also presumed to decrease. However, detailed information regarding the recent status of NCC in Korea is lacking. We retrospectively reviewed NCC cases from 1990 to 2016 at Asan Medical Center, a 2700-bed tertiary referral hospital in Korea. We identified patients based on clinical symptoms, brain imaging, pathology and serological assay. The cases were classified as parenchymal, extraparenchymal, and mixed NCC. Eighty-one patients were included in the analysis. The mean age was 54.5 years, and 79.0% were male. The number of NCC cases was highest from 1995 to 1999, and continuously decreased thereafter. Forty (49.4%) patients had parenchymal NCC, while 25 (30.9%) patients had extraparenchymal NCC, and 16 (19.8%) patients had mixed NCC. The seizure and headache were most common symptom of parenchymal NCC and extraparenchymal NCC respectively. Hydrocephalus was more common in extraparenchymal NCC, and patients with extraparenchymal NCC were more likely to require a ventriculoperitoneal shunt. Cases of NCC are decreasing accordingly with human taeniasis and lesion location was the most important determinant of clinical presentation and outcome of NCC in Korea.Entities:
Keywords: Korea; Taenia solium; human taeniasis; neurocysticercosis
Mesh:
Year: 2019 PMID: 31284349 PMCID: PMC6616162 DOI: 10.3347/kjp.2019.57.3.265
Source DB: PubMed Journal: Korean J Parasitol ISSN: 0023-4001 Impact factor: 1.341
Fig. 1Numbers of patients, age group distributions and median ages according to period of diagnosis. *Mean age at diagnosis.
Comparison of clinical and radiological characteristics of parenchymal, extraparenchymal and mixed neurocysticercosis
| Age at diagnosis, years (mean±S.D) | Parenchymal (n=40) (%) | Extra-parenchymal (n=25) (%) | Mixed (n=16) (%) | ||
|---|---|---|---|---|---|
|
|
|
|
|
| |
| 53.8±10.8 | 54.0±16.6 | 56.9±10.7 | 0.959 | 0.533 | |
| Sex | |||||
| Male | 35 (87.5) | 16 (64.0) | 13 (81.3) | 0.025 | 0.236 |
|
| |||||
| Symptoms | |||||
| Headache | 10 (25.0) | 16 (64.0) | 8 (50.0) | 0.002 | 0.375 |
| Seizure | 15 (37.5) | 0 (0) | 2 (12.5) | <0.001 | 0.146 |
| Gait disturbance | 4 (10.0) | 5 (20.0) | 3 (18.8) | 0.288 | 0.999 |
| Voiding difficulty | 2 (5.0) | 0 (0) | 0 (0) | 0.519 | N/A |
| Cranial nerve palsy | 4 (10.0) | 3 (12.0) | 1 (6.2) | 0.999 | 0.999 |
| Focal neurological deficit | 7 (17.5) | 3 (12.0) | 3 (18.8) | 0.729 | 0.662 |
|
| |||||
| Involvement of spinal cord | |||||
| Brain only | 37 (92.5) | 21 (84.0) | 14 (87.5) | 0.282 | 0.757 |
| Spinal cord only | 3 (7.5) | 4 (16.0) | 0 (0) | 0.415 | 0.143 |
| Brain and spinal cord | 0 (0) | 0 (0) | 2 (12.5) | N/A | 0.146 |
|
| |||||
| Image findings | |||||
| Subarachnoid cyst | 0 (0) | 22 (88.0) | 15 (93.8) | <0.001 | 0.545 |
| Intraventricular cyst | 0 (0) | 5 (20.0) | 2 (12.5) | 0.053 | 0.685 |
| Hydrocephalus | 5 (12.5) | 14 (56.0) | 4 (25.0) | <0.001 | 0.063 |
| Calcification | 26 (65.0) | 0 (0) | 2 (12.5) | 0.019 | 0.146 |
| Leptomeningeal enhancement | 3 (7.5) | 5 (20.0) | 3 (18.8) | 0.243 | 0.999 |
|
| |||||
| Method of diagnosis | |||||
| Positive pathology | 14 (35.0) | 9 (36.0) | 3 (18.8) | 0.935 | 0.305 |
| Positive CSF ELISA Ab | 27 (67.5) | 17 (68.0) | 13 (81.2) | 0.967 | 0.350 |
|
| |||||
| CSF characteristics | |||||
| Cells (/ml) | 37.2±109.9 | 46.0±42.3 | 69.2±79.9 | 0.758 | 0.338 |
| Protein (mg/dl) | 47.8±20.2 | 95.6±50.3 | 60.5±24.7 | 0.002 | 0.078 |
| Glucose (mg/dl) | 65.3±22.9 | 35.1±19.7 | 61.3±8.7 | <0.001 | 0.001 |
|
| |||||
| Surgical treatment | |||||
| Worm removal | 14 (35.0) | 12 (48.0) | 3 (18.8) | 0.298 | 0.097 |
| VP shunt | 1 (2.5) | 10 (40.0) | 6 (37.5) | <0.001 | 0.873 |
|
| |||||
| Follow-up period in months (mean±S.D) | 103.3±83.2 | 65.0±63.6 | 57.1±76.3 | 0.054 | 0.721 |
|
| |||||
| Clinical complication | 3 (7.5) | 6 (24.0) | 5 (31.2) | 0.076 | 0.609 |
| Spinal cord compression | 0 (0) | 2 (8.0) | 1 (6.2) | 0.144 | 0.999 |
| Vascular infarction | 0 (0) | 0 (0) | 1 (6.2) | N/A | 0.390 |
| Uncontrolled seizure | 2 (5.0) | 0 (0) | 0 (0) | 0.519 | N/A |
| Uncontrolled ICP | 1 (2.5) | 4 (16.0) | 2 (12.5) | 0.068 | 0.999 |
| Recurrent meningitis | 0 (0) | 0 (0) | 1 (6.2) | N/A | 0.390 |
P1: comparing parenchymal and extraparenchymal neurocysticercosis.
P2: comparing extraparenchymal and mixed neurocysticercosis.
S.D: standard deviation.
Fig. 2Number of patients according to lesion location. *Parenchymal disease included cases with the nodules, cysts or calcifications located only in the parenchyma. †Extraparenchymal disease included cases with cystic lesions in the ventricles or in the subarachnoid spaces. ‡Mixed disease included cases with both parenchymal and extraparenchymal lesions.